Ultimately, our methodology provides a promising solution for the development of targeted ROCK2 inhibitors, offering potential therapeutic avenues for conditions such as cancer metastasis, cardiovascular disorders, and neurodegenerative diseases by effectively mitigating the deleterious effects of ROCK2 dysregulation. This evidence concerns the gene ROCK2 and neurodegenerative disease.